MT. KISCO, N.Y., April 2, 2015 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) announces 1st quarter revenues rose more than 50%, year over year, to approximately $288,000. Additionally, as reported in its recent 10K, ImmuDyne is hiring additional sales and marketing executives, each with performance based contracts, allowing ImmuDyne to continue to manage strong expense controls.
ImmuDyne President and CEO, Mark McLaughlin commented, "ImmuDyne is beginning to commercialize many years of research and development, and our Science team will play an integral role in our future growth. Dr. Sven Rohmann, PhD, our Global Chief Medical Officer, is a worldwide authority on innate immunity, with an extensive medical and business background, including having spent 10 years with Merck Serono, where he served as the Global Head, Strategic Marketing, Oncology. Sven, along with ImmuDyne Director Dr. Joseph DiTrolio, a leading physician at The Stone Center of New Jersey, and Dr. Stephen Petteruti of The Petteruti Center For Life Extension, Warwick, RI, are among many experts that our sales team can count on, as ImmuDyne pursues opportunities to market our products and increase sales."
Additionally, the Company reports that recent test results of independent analytical comparison continue to demonstrate the superiority of ImmuDyne's beta glucan. These test results can be made available by ImmuDyne.
For more information about ImmuDyne's full line of products, call Todd Goldman at 813-444-1014 or go to www.immudyne.com.
ImmuDyne manufactures and sells proprietary, clinically researched, doctor-recommended, yeast beta-1,3/1,6 glucan immune support supplements and topical skin care products. ImmuDyne has a portfolio of unique proprietary and patent-protected products with applications in the wellness, skin care, anti-aging, fitness, and health markets. ImmuDyne has offices located in Mt. Kisco, NY, and Florence, KY. PURACERE, iNR Start, iNR Strength, iNR Wellness, and iNR Wellness MD are trademarks of ImmuDyne, Inc. ImmuDyne shares trade under the ticker symbol IMMD and the Company can be found on the web at www.immudyne.com.
Cautionary language regarding Forward-Looking Statements/Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.